Kitov Pharmaceuticals Ltd
Dr. Hadas Reuveni is a co-inventor of TyrNovo’s technology. She has been engaged with the scientific projects in TyrNovo’s portfolio since 2005, and has nearly two decades of research and development experience in biotechnology. Dr. Reuveni founded and served as CEO of NovoTyr, a biotech start-up company preceding TyrNovo that developed small molecules for the treatment of cancer and neurodegenerative diseases. She also founded and served as a Director and Chief Science Officer of AngioB, a startup that developed GPCR-based agents for multiple indications (2006-2010). Prior to that, she was the Director of Research & Development at Keryx Biopharmaceuticals (NASDAQ: KRX) in 2001-2004. Dr. Reuveni also has served as a scientific consultant for Integra Holdings, Campus Bio Management, and BioLineRX (NASDAQ/TASE: BLRX). Dr. Reuveni received her PhD from The Hebrew University of Jerusalem.